# A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study

> **NCT02658409** · PHASE3 · UNKNOWN · sponsor: **Green Cross Corporation** · enrollment: 1630 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GC3106(quadrivalent cell-culture based influenza vaccine)
- **BIOLOGICAL:** Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)

## Key facts

- **NCT ID:** NCT02658409
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2015-11
- **Final completion:** —
- **Target enrollment:** 1630 (ACTUAL)
- **Last updated:** 2016-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658409, "A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02658409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*